Decibel Therapeutics
Biotechnology ResearchView the employees at
Decibel Therapeutics-
John Lee Chief Development Officer at Decibel Therapeutics
-
Cambridge
-
Top 10%
Kathryn Ellis Sr. Director, Head of Discovery Programs-
Boston, Massachusetts, United States
-
Rising Star
Jason Riggs Sr. Clinical Scientist-
United States
-
Rising Star
Overview
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of building a world of connection for people with hearing and balance disorders. Guidelines: https://bit.ly/3IzmNvU
-